103 related articles for article (PubMed ID: 23085831)
1. Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation.
Helton KJ; Patay Z; Triplett BM
Bone Marrow Transplant; 2013 May; 48(5):729-31. PubMed ID: 23085831
[No Abstract] [Full Text] [Related]
2. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
3. [Conditioning regimen containing fludarabine instead of cyclophosphamide for haploidentical hematopoietic stem cell transplantation].
Chen HR; He XP; Si YJ; Yang K; Hu B; DU ZL; Zhang XM; Zhang CC
Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):514-8. PubMed ID: 19954636
[TBL] [Abstract][Full Text] [Related]
4. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Zohren F; Czibere A; Bruns I; Fenk R; Schroeder T; Gräf T; Haas R; Kobbe G
Bone Marrow Transplant; 2009 Dec; 44(12):785-92. PubMed ID: 19430496
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL.
Ussowicz M; Musiał J; Duszeńko E; Haus O; Kałwak K
Bone Marrow Transplant; 2013 May; 48(5):740-1. PubMed ID: 23103677
[No Abstract] [Full Text] [Related]
8. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
10. Unrelated cord blood transplantation in a Fanconi anemia patient using fludarabine-based conditioning.
de Medeiros CR; Silva LM; Pasquini R
Bone Marrow Transplant; 2001 Jul; 28(1):110-2. PubMed ID: 11498756
[No Abstract] [Full Text] [Related]
11. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
12. [Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].
Wu DP; Ma X; Sun AN; Fu ZZ; Tang XW; Qiu HY; Miao M; Liu YJ; Li CX; Xia XM; Lin BJ
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):410-2. PubMed ID: 14642177
[TBL] [Abstract][Full Text] [Related]
13. Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
Mielke S; Potthoff K; Feuerhake F; Bley TA; Windfuhr M; Bertz H; Finke J
Onkologie; 2007 Feb; 30(1-2):49-52. PubMed ID: 17264526
[TBL] [Abstract][Full Text] [Related]
14. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
[TBL] [Abstract][Full Text] [Related]
15. Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
Wong AM; Allen JC; Goh YT; Linn YC; Loh SM; Diong CP; Chowbay B; Hwang WY
Bone Marrow Transplant; 2012 Feb; 47(2):181-9. PubMed ID: 21478919
[TBL] [Abstract][Full Text] [Related]
16. Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
Busemann C; Wilfert H; Neumann T; Kiefer T; Dölken G; Krüger WH
Onkologie; 2011; 34(10):518-24. PubMed ID: 21985850
[TBL] [Abstract][Full Text] [Related]
17. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation.
Beitinjaneh A; McKinney AM; Cao Q; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Mar; 17(3):300-8. PubMed ID: 20399878
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
[TBL] [Abstract][Full Text] [Related]
19. The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.
Hamidieh A; Kargar M; Jahani M; Alimoghaddam K; Bahar B; Mousavi SA; Iravani M; Jalali A; Jalili M; Ghavamzadeh A
J Pediatr Hematol Oncol; 2012 Mar; 34(2):101-7. PubMed ID: 22367385
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.
Tendas A; Cupelli L; Dentamaro T; Scaramucci L; Palumbo R; Niscola P; Giovannini M; Piccioni D; Perrotti AP; de Fabritiis P
Ann Hematol; 2009 Mar; 88(3):285-6. PubMed ID: 18690439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
